Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin

Lung cancer is the leading cause of death of all cancer entities and small-cell lung cancer (SCLC) is the most malignant subtype. Despite good initial response to chemotherapy, many patients relapse early and success of second line treatment remains poor. For years, no relevant improvement of second...

Descripción completa

Detalles Bibliográficos
Autores principales: Kauffmann-Guerrero, Diego, Huber, Rudolf Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060031/
https://www.ncbi.nlm.nih.gov/pubmed/32184690
http://dx.doi.org/10.2147/LCTT.S239223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060031/
https://www.ncbi.nlm.nih.gov/pubmed/32184690
http://dx.doi.org/10.2147/LCTT.S239223

Ejemplares similares